Sanofi (SNY) Equity Income (2009 - 2026)

Sanofi (SNY) has 18 years of Equity Income data on file, last reported at $12.9 million in Q1 2026.

• Quarterly Equity Income fell 70.85% year-over-year to $12.9 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was -$231.7 million (down 263.57% YoY) and the FY2025 annual result came in at -$180.4 million, down 381.41% from the prior year.
• Equity Income grew to $12.9 million in Q1 2026 per SNY's latest filing, from -$277.0 million in the prior quarter.
• The five-year high for Equity Income was $97.0 million in Q3 2025, with the low at -$277.0 million in Q4 2025.
• Average Equity Income over 5 years is -$11.5 million, with a median of $12.9 million recorded in 2026.
• Year-over-year, Equity Income jumped 902.54% in 2023 and tumbled 5085.17% in 2025.
• Sanofi's Equity Income stood at $3.1 million in 2022, then tumbled by 4880.8% to -$146.3 million in 2023, then jumped by 96.35% to -$5.3 million in 2024, then plunged by 5085.17% to -$277.0 million in 2025, then jumped by 104.65% to $12.9 million in 2026.
• Business Quant data shows SNY's Equity Income at $12.9 million in Q1 2026, -$277.0 million in Q4 2025, and $97.0 million in Q3 2025.